-
Analysis of Cell-Free DNA in Maternal Blood in Screening For Aneuploidies: Updated Meta-Analysis.
Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:302-314. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities.
Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:174-84. pdf -
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
Prenat Diagn 2011;31:38-45. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;28:637-43. -
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:949-53. -
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
Bersinger NA, Noble P, Nicolaides KH.
Prenat Diagn 2003;23:157-62. -
First trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
Spencer K, Noble P, Snijders RJ, Nicolaides KH.
Prenat Diagn 1997;17:525-38. -
Perinatal features associated with placental mesenchymal dysplasia.
Jauniaux E, Nicolaides KH, Hustin J.
Placenta 1997;18:701-6. -
Maternal serum concentrations of pregnancy associated plasma protein A and pregnancy specific B-1 glycoprotein in multifetal pregnancies before and after fetal reduction.
Abbas A, Sebire NJ, Johnson M, Bersinger N, Nicolaides KH.
Hum Reprod 1996;11,900-2.